Immune mediated colitis caused by lung cancer treatment with atezolizumab

González-Vázquez, Santiago; de-la-Riva-Onandía, Susana; Echeveste, José Ignacio; Muñoz-Navas, Miguel.
Rev. esp. enferm. dig ; 109(12): 863-864, dic. 2017. ilus
Artículo en Inglés | IBECS (España) | ID: ibc-169195

Documentos relacionados

  1. Immune mediated colitis caused by lung cancer treatment with atezolizumab.
  2. Checkpoint inhibitors and gastrointestinal immune-related adverse events.
  3. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.
  4. Checkpoint Inhibitor-Induced Colitis.
  5. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
  6. Treatment of Immune Checkpoint Inhibitor Induced Colitis with Infliximab.
  7. <i>Bifidobacterium</i> can mitigate intestinal immunopathology in the context of CTLA-4 blockade.
  8. Hemorrhagic Colitis Caused by Everolimus in a Patient with Nonfunctional Pancreatic Neuroendocrine Neoplasms: A Case Report.
  9. Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer.
  10. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.